Aging in COVID-19: Vulnerability, immunity and intervention
Tóm tắt
Từ khóa
Tài liệu tham khảo
Arons, 2020, Presymptomatic SARS-CoV-2 infections and transmission in a skilled nursing facility, N. Engl. J. Med., 382, 2081, 10.1056/NEJMoa2008457
Arvin, 2020, A perspective on potential antibody-dependent enhancement of SARS-CoV-2, Nature, 584, 353, 10.1038/s41586-020-2538-8
Baig, 2020, Evidence of the COVID-19 virus targeting the CNS: tissue distribution, host-virus interaction, and proposed neurotropic mechanisms, ACS Chem. Neurosci., 11, 995, 10.1021/acschemneuro.0c00122
Bourgonje, 2020, Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19), J. Pathol., 251, 228, 10.1002/path.5471
Braun, 2020, SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19, Nature, 2020
CDC, 2020, Severe outcomes among patients with coronavirus disease 2019 (COVID-19) - United States, February 12-March 16, 2020, Morb. Mortal. Wkly. Rep., 69, 343, 10.15585/mmwr.mm6912e2
Chan, 2020, Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan, Emerg. Microbes Infect., 9, 221, 10.1080/22221751.2020.1719902
Chen, 2019, Chronic low-grade inflammatory phenotype (CLIP) and senescent immune dysregulation, Clin. Ther., 41, 400, 10.1016/j.clinthera.2019.02.001
Chen, 2020, Medical Treatment Expert Group for, C., 2020c. Longitudinal hematologic and immunologic variations associated with the progression of COVID-19 patients in China, J. Allergy Clin. Immunol., 146, 89, 10.1016/j.jaci.2020.05.003
Chen, 2020, Clinical and immunological features of severe and moderate coronavirus disease 2019, J. Clin. Invest., 130, 2620, 10.1172/JCI137244
Chen, 2020, The clinical and immunological features of pediatric COVID-19 patients in China, Genes Dis., 2020
Cui, 2019, Origin and evolution of pathogenic coronaviruses, Nat. Rev. Microbiol., 17, 181, 10.1038/s41579-018-0118-9
de Wit, 2016, SARS and MERS: recent insights into emerging coronaviruses, Nat. Rev. Microbiol., 14, 523, 10.1038/nrmicro.2016.81
Della-Torre, 2020, Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study, Ann. Rheum. Dis., 79, 1277, 10.1136/annrheumdis-2020-218122
Diamond, 2020, The challenges of vaccine development against a new virus during a pandemic, Cell Host Microbe, 27, 699, 10.1016/j.chom.2020.04.021
Duan, 2020, Effectiveness of convalescent plasma therapy in severe COVID-19 patients, Proc. Natl. Acad. Sci. U. S. A., 117, 9490, 10.1073/pnas.2004168117
Fang, 2015, A research agenda for aging in China in the 21st century, Ageing Res. Rev., 24, 197, 10.1016/j.arr.2015.08.003
Ferrarese, 2020, An Italian multicenter retrospective-prospective observational study on neurological manifestations of COVID-19 (NEUROCOVID), Neurol. Sci., 41, 1355, 10.1007/s10072-020-04450-1
Folegatti, 2020, Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial, Lancet., 396, 467, 10.1016/S0140-6736(20)31604-4
Franceschi, 2014, Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases, J. Gerontol. A Biol. Sci. Med. Sci., 69, S4, 10.1093/gerona/glu057
Franceschi, 2000, Inflamm-aging. An evolutionary perspective on immunosenescence, Ann. N. Y. Acad. Sci., 908, 244, 10.1111/j.1749-6632.2000.tb06651.x
Franceschi, 2017, Inflammaging and’ Garb-aging’, Trends Endocrinol. Metab., 28, 199, 10.1016/j.tem.2016.09.005
Frontera, 2020, Global consortium study of neurological dysfunction in COVID-19 (GCS-NeuroCOVID): study design and rationale, Neurocrit. Care, 33, 25, 10.1007/s12028-020-00995-3
Fung, 2020, A tug-of-war between severe acute respiratory syndrome coronavirus 2 and host antiviral defence: lessons from other pathogenic viruses, Emerg. Microbes Infect., 9, 558, 10.1080/22221751.2020.1736644
Gao, 2020, A systematic review of asymptomatic infections with COVID-19, J. Microbiol. Immunol. Infect., 2020
Garibaldi, 2020, Patient Trajectories Among Persons Hospitalized for COVID-19 : A Cohort Study, Ann Intern Med, M20
Gheblawi, 2020, Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system: celebrating the 20th anniversary of the discovery of ACE2, Circ. Res., 126, 1456, 10.1161/CIRCRESAHA.120.317015
Grifoni, 2020, Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals, Cell., 181, 1489, 10.1016/j.cell.2020.05.015
Gupta, 2020, A comparative analysis of control measures on-board ship against COVID-19 and similar novel viral respiratory disease outbreak: quarantine ship or disembark suspects?, Med. J. Armed Forces India, 2020
Halamka, 2020, Redesigning COVID 19 care with network medicine and machine learning: a review, Mayo Clin. Proc. Innov. Qual. Outcomes., 2020
Harvala, 2020, Convalescent plasma treatment for SARS-CoV-2 infection: analysis of the first 436 donors in England, 22 April to 12 May 2020, Euro Surveill., 25, 10.2807/1560-7917.ES.2020.25.28.2001260
Hatchett, 2007, Public health interventions and epidemic intensity during the 1918 influenza pandemic, Proc. Natl. Acad. Sci. U. S. A., 104, 7582, 10.1073/pnas.0610941104
Hegerova, 2020, Use of convalescent plasma in hospitalized patients with COVID-19: case series, Blood, 136, 759, 10.1182/blood.2020006964
Heink, 2017, Trans-presentation of IL-6 by dendritic cells is required for the priming of pathogenic TH17 cells, Nat. Immunol., 18, 74, 10.1038/ni.3632
Hoffmann, 2020, SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor, Cell, 181, 271, 10.1016/j.cell.2020.02.052
Jackson, 2020, An mRNA vaccine against SARS-CoV-2 - preliminary report, N. Engl. J. Med., 2020
Jose, 2020, COVID-19 cytokine storm: the interplay between inflammation and coagulation, Lancet Respir. Med., 8, e46, 10.1016/S2213-2600(20)30216-2
Joyner, 2020, Early safety indicators of COVID-19 convalescent plasma in 5,000 patients, J. Clin. Invest., 130, 4791, 10.1172/JCI140200
Kadambari, 2020, Why the elderly appear to be more severely affected by COVID-19: the potential role of immunosenescence and CMV, Rev. Med. Virol., e2144, 10.1002/rmv.2144
Kang, 2019, Targeting Interleukin-6 signaling in clinic, Immunity, 50, 1007, 10.1016/j.immuni.2019.03.026
Kang, 2020, Aberrant hyperactivation of cytotoxic T-cell as a potential determinant of COVID-19 severity, Int. J. Infect. Dis., 97, 313, 10.1016/j.ijid.2020.05.106
Kim, 2016, Enhanced viral replication by cellular replicative senescence, Immune Netw., 16, 286, 10.4110/in.2016.16.5.286
Kim, 2018, Influenza virus: dealing with a drifting and shifting pathogen, Viral Immunol., 31, 174, 10.1089/vim.2017.0141
Klein, 2020, Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population, medRxiv, 2020
Korber, 2020, Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus, Cell, 182, 812, 10.1016/j.cell.2020.06.043
Kupferschmidt, 2020, The pandemic virus is slowly mutating. But does it matter?, Science, 369, 238, 10.1126/science.369.6501.238
Lagunas-Rangel, 2020, High IL-6/IFN-gamma ratio could be associated with severe disease in COVID-19 patients, J. Med. Virol., 2020
Lalmuanawma, 2020, Applications of machine learning and artificial intelligence for Covid-19 (SARS-CoV-2) pandemic: a review, Chaos Solitons Fractals, 139, 10.1016/j.chaos.2020.110059
Lambert, 2020, Consensus summary report for CEPI/BC March 12-13, 2020 meeting: assessment of risk of disease enhancement with COVID-19 vaccines, Vaccine., 38, 4783, 10.1016/j.vaccine.2020.05.064
Leonardi, 2020, Neurological manifestations associated with COVID-19: a review and a call for action, J. Neurol., 267, 1573, 10.1007/s00415-020-09896-z
Li, 2011, Frailty, inflammation, and immunity, Aging Dis., 2, 466
Li, 2018, The aging tsunami and senior healthcare development in China, J. Am. Geriatr. Soc., 66, 1462, 10.1111/jgs.15424
Li, 2020, Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial, JAMA., 324, 460, 10.1001/jama.2020.10044
Lin, 2020, Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia, Emerg. Microbes Infect., 9, 727, 10.1080/22221751.2020.1746199
Lingappan, 2020, Understanding the age divide in COVID-19: why are children overwhelmingly spared?, Am. J. Physiol. Lung Cell Mol. Physiol., 319, L39, 10.1152/ajplung.00183.2020
Liu, 2020, A preliminary study on serological assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 238 admitted hospital patients, Microbes Infect., 22, 206, 10.1016/j.micinf.2020.05.008
Liu, 2020, Thymosin alpha 1 (Talpha1) reduces the mortality of severe COVID-19 by restoration of lymphocytopenia and reversion of exhausted T cells, Clin. Infect. Dis., 2020
Lurie, 2020, The development of COVID-19 vaccines: safeguards needed, JAMA, 324, 439, 10.1001/jama.2020.12461
Lyons, 2018, 10
Mackman, 2020, Coagulation abnormalities and thrombosis in patients infected with SARS-CoV-2 and other pandemic viruses, Arterioscler. Thromb. Vasc. Biol., 40, 2033, 10.1161/ATVBAHA.120.314514
Maggio, 2006, Interleukin-6 in aging and chronic disease: a magnificent pathway, J. Gerontol. A Biol. Sci. Med. Sci., 61, 575, 10.1093/gerona/61.6.575
Magro, 2020, Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases, Transl. Res., 220, 1, 10.1016/j.trsl.2020.04.007
Manners, 2020, Protective adaptive immunity against severe acute respiratory syndrome coronaviruses 2 (SARS-CoV-2) and implications for vaccines, Cureus., 12, e8399
Mateus, 2020, Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans, Science, 370, 89, 10.1126/science.abd3871
Mathew, 2020, Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications, Science., 369, 8511, 10.1126/science.abc8511
McMichael, 2020, Epidemiology of Covid-19 in a Long-term care facility in King County, Washington, N. Engl. J. Med., 382, 2005, 10.1056/NEJMoa2005412
Meckiff, 2020, Single-cell transcriptomic analysis of SARS-CoV-2 reactive CD4 (+) T cells, bioRxiv, 2020
Minaee, 2020, Deep-COVID: predicting COVID-19 from chest X-ray images using deep transfer learning, Med. Image Anal., 65, 10.1016/j.media.2020.101794
Mittal, 2020, COVID-19 pandemic: insights into structure, function, and hACE2 receptor recognition by SARS-CoV-2, PLoS Pathog., 16, 10.1371/journal.ppat.1008762
Moore, 2020, Cytokine release syndrome in severe COVID-19, Science, 368, 473, 10.1126/science.abb8925
Moratto, 2020, Immune response in children with COVID-19 is characterized by lower levels of T-cell activation than infected adults, Eur. J. Immunol., 2020
Moss, 2020, The ancient and the new": is there an interaction between cytomegalovirus and SARS-CoV-2 infection?, Immun. Ageing, 17, 14, 10.1186/s12979-020-00185-x
Neidleman, 2020, SARS-CoV-2-specific T cells exhibit unique features characterized by robust helper function, lack of terminal differentiation, and high proliferative potential, bioRxiv, 2020
Netea, 2020, Defining trained immunity and its role in health and disease, Nat. Rev. Immunol., 20, 375, 10.1038/s41577-020-0285-6
Ng, 2016, Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection, Vaccine, 34, 2008, 10.1016/j.vaccine.2016.02.063
Ni, 2020, Detection of SARS-CoV-2-Specific humoral and cellular immunity in COVID-19 convalescent individuals, Immunity, 52, 971, 10.1016/j.immuni.2020.04.023
Nicoli, 2020, Age-related decline of de novo T cell responsiveness as a cause of COVID-19 severity, Geroscience, 42, 1015, 10.1007/s11357-020-00217-w
Noris, 2020, The case of complement activation in COVID-19 multiorgan impact, Kidney Int., 98, 314, 10.1016/j.kint.2020.05.013
Oh, 2011, Engineering T cells specific for a dominant severe acute respiratory syndrome coronavirus CD8 T cell epitope, J. Virol., 85, 10464, 10.1128/JVI.05039-11
Onder, 2020, Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy, JAMA., 323, 1775
Paules, 2017, The pathway to a universal influenza vaccine, Immunity., 47, 599, 10.1016/j.immuni.2017.09.007
Pawelec, 2018, Age and immunity: what is “immunosenescence”?, Exp. Gerontol., 105, 4, 10.1016/j.exger.2017.10.024
Pawelec, 2020, Can an effective SARS-CoV-2 vaccine be developed for the older population?, Immun. Ageing, 17, 8, 10.1186/s12979-020-00180-2
Peng, 2020, Broad and strong memory CD4 (+) and CD8 (+) T cells induced by SARS-CoV-2 in UK convalescent COVID-19 patients, bioRxiv, 2020
Petersen, 2020, Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics, Lancet Infect. Dis., 20, e238, 10.1016/S1473-3099(20)30484-9
Puelles, 2020, Multiorgan and renal tropism of SARS-CoV-2, N. Engl. J. Med., 383, 590, 10.1056/NEJMc2011400
Qin, 2020, Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China, Clin. Infect. Dis., 71, 762, 10.1093/cid/ciaa248
Radzikowska, 2020, Distribution of ACE2, CD147, CD26 and other SARS-CoV-2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID-19 risk factors, Allergy, 2020
Randad, 2020, COVID-19 serology at population scale: SARS-CoV-2-specific antibody responses in saliva, medRxiv, 2020
Rehman, 2020, Current scenario of COVID-19 in pediatric age group and physiology of immune and thymus response, Saudi J. Biol. Sci., 27, 2567, 10.1016/j.sjbs.2020.05.024
Richardson, 2020, Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area, JAMA, 323, 2052, 10.1001/jama.2020.6775
Rosenberg, 2020, COVID-19 testing, epidemic features, hospital outcomes, and household prevalence, New York state-march 2020, Clin. Infect. Dis., 2020
Rothe, 2020, Transmission of 2019-nCoV infection from an asymptomatic contact in Germany, N. Engl. J. Med., 382, 970, 10.1056/NEJMc2001468
Sajadi, 2020, Temperature, humidity, and latitude analysis to estimate potential spread and seasonality of coronavirus disease 2019 (COVID-19), JAMA Netw. Open., 3, 10.1001/jamanetworkopen.2020.11834
Salje, 2020, Estimating the burden of SARS-CoV-2 in France, Science., 369, 208, 10.1126/science.abc3517
Sallard, 2020, Type 1 interferons as a potential treatment against COVID-19, Antiviral Res., 178, 10.1016/j.antiviral.2020.104791
Sanchez-Cerrillo, 2020, Differential redistribution of activated monocyte and dendritic cell subsets to the lung associates with severity of COVID-19, medRxiv, 2020
Sette, 2020, Pre-existing immunity to SARS-CoV-2: the knowns and unknowns, Nat. Rev. Immunol., 20, 457, 10.1038/s41577-020-0389-z
Shen, 2020, Treatment of 5 critically ill patients with COVID-19 with convalescent plasma, JAMA., 323, 1582, 10.1001/jama.2020.4783
Su, 2016, Epidemiology, genetic recombination, and pathogenesis of coronaviruses, Trends Microbiol., 24, 490, 10.1016/j.tim.2016.03.003
Tabari, 2020, International public health responses to COVID-19 outbreak: a rapid review, Iran. J. Med. Sci., 45, 157
Tay, 2020, The trinity of COVID-19: immunity, inflammation and intervention, Nat. Rev. Immunol., 20, 363, 10.1038/s41577-020-0311-8
Te Velthuis, 2016, Influenza virus RNA polymerase: insights into the mechanisms of viral RNA synthesis, Nat. Rev. Microbiol., 14, 479, 10.1038/nrmicro.2016.87
Thakar, 2015, Aging-dependent alterations in gene expression and a mitochondrial signature of responsiveness to human influenza vaccination, Aging (Albany N. Y.)., 7, 38
Thanh Le, 2020, The COVID-19 vaccine development landscape, Nat. Rev. Drug Discov., 19, 305, 10.1038/d41573-020-00073-5
Viner, 2020, Kawasaki-like disease: emerging complication during the COVID-19 pandemic, Lancet., 395, 1741, 10.1016/S0140-6736(20)31129-6
Wan, 2020, Molecular mechanism for antibody-dependent enhancement of coronavirus entry, J. Virol., 94
Wang, 2020, Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia, J. Infect. Dis., 221, 1762, 10.1093/infdis/jiaa150
Wang, 2020, Clinical manifestations and evidence of neurological involvement in 2019 novel coronavirus SARS-CoV-2: a systematic review and meta-analysis, J. Neurol., 267, 2777, 10.1007/s00415-020-09974-2
Weiskopf, 2020, Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome, Sci. Immunol., 5, 2071, 10.1126/sciimmunol.abd2071
Welsh, 2012, Type 1 interferons and antiviral CD8 T-cell responses, PLoS Pathog., 8, 10.1371/journal.ppat.1002352
Wiersinga, 2020, Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review, JAMA, 324, 782, 10.1001/jama.2020.12839
Wu, 2020, Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese center for disease control and prevention, JAMA., 323, 1239, 10.1001/jama.2020.2648
Wu, 2020, TH17 responses in cytokine storm of COVID-19: an emerging target of JAK2 inhibitor Fedratinib, J. Microbiol. Immunol. Infect., 53, 368, 10.1016/j.jmii.2020.03.005
Wu, 2020, Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China, JAMA Intern. Med., 10.1001/jamainternmed.2020.0994
Yang, 2020, Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19, J. Allergy Clin. Immunol., 146, 119, 10.1016/j.jaci.2020.04.027
Yao, 2011, Frailty is associated with impairment of vaccine-induced antibody response and increase in post-vaccination influenza infection in community-dwelling older adults, Vaccine., 29, 5015, 10.1016/j.vaccine.2011.04.077
Yip, 2019, 10 years of health-care reform in China: progress and gaps in universal health coverage, Lancet., 394, 1192, 10.1016/S0140-6736(19)32136-1
Zaki, 2012, Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia, N. Engl. J. Med., 367, 1814, 10.1056/NEJMoa1211721
Zhang, 2020, Treatment with convalescent plasma for critically ill patients with severe acute respiratory syndrome coronavirus 2 infection, Chest, 158, e9, 10.1016/j.chest.2020.03.039
Zhang, 2020, Immune phenotyping based on the neutrophil-to-lymphocyte ratio and igg level predicts disease severity and outcome for patients with COVID-19, Front. Mol. Biosci., 7, 157, 10.3389/fmolb.2020.00157
Zhang, 2020, Is aberrant CD8+ T cell activation by hypertension associated with cardiac injury in severe cases of COVID-19?, Cell. Mol. Immunol., 17, 675, 10.1038/s41423-020-0454-3
Zhao, 2020, Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019, Clin. Infect. Dis., 2020
Zhong, 2003, Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People’s Republic of China, in February, 2003, Lancet., 362, 1353, 10.1016/S0140-6736(03)14630-2
Zhou, 2020, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet., 395, 1054, 10.1016/S0140-6736(20)30566-3
Zhou, 2020, A pneumonia outbreak associated with a new coronavirus of probable bat origin, Nature., 579, 270, 10.1038/s41586-020-2012-7
Zhu, 2020, Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial, Lancet, 396, 479, 10.1016/S0140-6736(20)31605-6